Dekalb Medical Ctr-Pathology is categorized under Internal Medicine Doctors in Decatur, GA and active since 2011.
Dekalb Medical Ctr-Pathology was established in 2011, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Internal Medicine Doctors business, which does work in the B2C market, and is classified as a Internal Medicine Doctors, under code number 6215112 by the NAICS.
If you are seeking more information, feel free to contact Raoul Mayer at the company’s branch by writing to 2701 North Decatur Road, Decatur, Georgia GA 30033 or by phoning (404) 501-5256. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Dekalb Medical Ctr-Pathology |
Contact Person: | Raoul Mayer |
Address: | 2701 North Decatur Road, Decatur, Georgia 30033 |
Phone Number: | (404) 501-5256 |
Website Address: | dekalbmedical.org |
Annual Revenue (USD): | $1.000.000 to $2.499.999 |
Founded: | 2011 |
Location Type: | Branch |
Employee Number: | 1 to 4 |
Business Type: | B2C (Business to Consumer) |
Business Category: | Internal Medicine Doctors |
SIC Code: | 8011 |
NAICS Code: | 6215112 |
Share This Business: |
Dekalb Medical Ctr-Pathology was started in 2011 to provide professional Internal Medicine Doctors under the SIC code 8011 and NAICS code 6215112. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Raoul Mayer for inquiries that concern Dekalb Medical Ctr-Pathology by calling the company number (404) 501-5256, as your correspondence is most welcome. Additionally, the physical location of the branch of Dekalb Medical Ctr-Pathology can be found at the coordinates 33.79232,-84.282 as well as the street address 2701 North Decatur Road in Decatur, Georgia 30033.
For its online presence, you may visit Dekalb Medical Ctr-Pathology’s website at dekalbmedical.org and engage with its social media outlets through on Twitter and on Facebook.